NCT06934811View on ClinicalTrials.gov

Ciprofol's Impact on Oxygenator Function in Extracorporeal Membrane Oxygenation (ECMO) Patients

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
ECMO TreatmentARDS (Acute Respiratory Distress Syndrome)ECMO and Acute MIRespiratory Failure Patients Treated With ECMOShock, Cardiogenic
Interventions
DRUG

Ciprofol

Continuous intravenous infusion (0.05-0.3 mg/kg/h), adjusted hourly based on the RASS score (target range: -3 to 0).

DRUG

Midazolam

Continuous intravenous infusion (0.02-0.1 mg/kg/h), adjusted hourly based on the RASS score (target range: -3 to 0).

All Listed Sponsors
lead

First Affiliated Hospital of Wannan Medical College

OTHER